Hemolytic-Uremic Syndrome clinical trials at UCLA

1 in progress, 0 open to eligible people

Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
Sorry, in progress, not accepting new patients
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Los Angeles, California and other locations

Last updated: December 10, 2025